Learn About the Latest in Peripheral Nerve Research
The Peripheral Nerve Society (PNS) is a global non-profit group made up of doctors, scientists, and healthcare workers. They study and treat diseases of the peripheral nervous system.
Each year, the PNS hosts the PNS Annual Meeting. This event brings experts from around the world to share the newest research about peripheral nerve diseases. It’s the largest meeting in the world focused only on peripheral nerves. It’s a great chance for doctors and researchers to learn and connect.
2025 PNS Annual Meeting Held in Edinburgh, Scotland
The 2025 PNS Annual Meeting took place in Edinburgh, Scotland from May 17-20. Our executive director, Lindsay Colbert, went to this year’s meeting. She sat in many exciting talks about research projects that could help people living with neuropathy. Here are the projects that the Foundation is most excited about for the neuropathy community:
Decrease in progression of diabetic neuropathy in patients on GLP1 agonists
If GLP agonists prevent the progression of type 2 diabetes, it would be the first medication to do so. Experts hope to see more trials with this medication. If effective, there could be better treatment options for diabetic neuropathy on the horizon.
Creating an application and initial survey plus quantitative sensory testing to identify hereditary TTR amyloid neuropathy earlier in Primary Care Physician (PCP) offices
With new tests, experts can identify amyloid neuropathy earlier on. Patients are often several years into their symptoms before being diagnosed. Delays in diagnosis delay treatment. Creating easier ways for primary care physicians to identify neuropathy in their office and expedite referrals to a specialist, would be great for patient care.
Ever-increasing data, creating mouse models for various Charcot-Marie-Tooth (CMT) presentations
The more mouse models that neuropathy researchers create in the lab, the easier it is to test potential treatments. More data speeds up the process to get treatments to patients impacted by CMT.
Potential efficacy of complement inhibitors in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): a new class of medications for treatment
New options for treating CIDP are being developed. Increasing the types of treatments is beneficial to patients who don’t respond well to IVIg therapy. IVIg therapy is a treatment that involves the administration of antibodies (immunoglobulins) into the bloodstream to help boost the immune system. This helps combat infections and manage autoimmune and inflammatory conditions.
Further real-world effectiveness of subcu IGG, efgartigimod studies
The new studies on subcu IGG suggest this is something both doable and effective for CIDP patients. Subcu IGG stands for subcutaneous immunoglobulin G. It refers to giving immunoglobulin G (IgG) antibodies directly into the fatty tissue under the skin. This is an alternative to intravenous immunoglobulin (IVIg) therapy, where antibodies are administered in a vein.
Work on creating biomarkers for future CMT studies
Biomarker studies are important. Experts don’t currently have good ways to monitor disease progression in a slowly progressive disorder like CMT, so finding biomarkers is key. Tracking progress during a treatment trial is important for evaluating new treatments, to understand if they are working or not.
About PNS
PNS supports basic and clinical research, education and standards of care in cooperation with patients and those developing treatments. Learn more about membership, grants and education on the PNS website.
